TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Controlled, Comparative Efficacy and Safety Study of Topical Recombinant Human Thrombin (rhThrombin) and Thrombin-JMI (Bovine Thrombin) in Surgical Hemostasis
Brief Summary: The purpose of this study is to determine whether recombinant human Thrombin (rhThrombin) is effective in stopping bleeding during surgery, in comparison with bovine thrombin.


Options:
A: Arm Label: Haemocomplettan® P; Type: ACTIVE_COMPARATOR; Interventions: Biological: Haemocomplettan® P | Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline solution | Intervention Type: BIOLOGICAL; Name: Haemocomplettan® P; Assigned to Arm(s): Haemocomplettan® P | Intervention Type: BIOLOGICAL; Name: Saline solution; Assigned to Arm(s): Saline solution
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol controlled release (CR) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol controlled release (CR); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
C: Arm Label: Fibrocaps + Gelatin Sponge; Type: EXPERIMENTAL; Interventions: Biological: Fibrocaps, Biological: Gelatin sponge | Arm Label: Gelatin Sponge; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gelatin sponge | Intervention Type: BIOLOGICAL; Name: Fibrocaps; Assigned to Arm(s): Fibrocaps + Gelatin Sponge | Intervention Type: BIOLOGICAL; Name: Gelatin sponge; Assigned to Arm(s): Fibrocaps + Gelatin Sponge, Gelatin Sponge
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: rThrombin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: bovine thrombin | Intervention Type: BIOLOGICAL; Name: rThrombin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: bovine thrombin; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Diabetes Telemonitoring (DiaTel) Study
Brief Summary: The purpose of this research study is to compare two different methods of helping veterans with diabetes better manage their disease. This study will compare an "Active Care Management" method using home-based technology and self-monitoring techniques with a lower-intensity "Care Coordination" method based on monthly telephone contact with a nurse.


Options:
A: Arm Label: Care Coordination; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Care Coordination | Arm Label: Home Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home Telemedicine | Intervention Type: BEHAVIORAL; Name: Care Coordination; Assigned to Arm(s): Care Coordination | Intervention Type: BEHAVIORAL; Name: Home Telemedicine; Assigned to Arm(s): Home Telemedicine
B: Arm Label: Intervention; Type: OTHER; Interventions: Behavioral: Vascular Management Program, Behavioral: Clinical Care Coordinators, Behavioral: Web-based Vascular Tracker for Patient and Physician, Behavioral: Automated Telephone Reminder System | Intervention Type: BEHAVIORAL; Name: Vascular Management Program; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Clinical Care Coordinators; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Web-based Vascular Tracker for Patient and Physician; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Automated Telephone Reminder System; Assigned to Arm(s): Intervention
C: Arm Label: Technology-based self-management model; Type: EXPERIMENTAL; Interventions: Device: Technology-based self-management model | Arm Label: Conventional self-management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Technology-based self-management model; Assigned to Arm(s): Technology-based self-management model
D: Arm Label: Participants with type 2 diabetes mellitus (T2DM); Type: N/A; Interventions: Other: No treatment given | Intervention Type: OTHER; Name: No treatment given; Assigned to Arm(s): Participants with type 2 diabetes mellitus (T2DM)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Diabetes Telemonitoring (DiaTel) Study
Brief Summary: The purpose of this research study is to compare two different methods of helping veterans with diabetes better manage their disease. This study will compare an "Active Care Management" method using home-based technology and self-monitoring techniques with a lower-intensity "Care Coordination" method based on monthly telephone contact with a nurse.


Options:
A: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Telephone behavioral education, Behavioral: Computer behavioral education | Intervention Type: BEHAVIORAL; Name: Telephone behavioral education; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Computer behavioral education; Assigned to Arm(s): Arm 1
B: Arm Label: Home Monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Home Monitoring | Arm Label: In-Office Conventional Follow-up; Type: OTHER; Interventions: Other: In-Office Conventional Follow-up | Intervention Type: OTHER; Name: Home Monitoring; Assigned to Arm(s): Home Monitoring | Intervention Type: OTHER; Name: In-Office Conventional Follow-up; Assigned to Arm(s): In-Office Conventional Follow-up
C: Arm Label: Care Coordination; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Care Coordination | Arm Label: Home Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home Telemedicine | Intervention Type: BEHAVIORAL; Name: Care Coordination; Assigned to Arm(s): Care Coordination | Intervention Type: BEHAVIORAL; Name: Home Telemedicine; Assigned to Arm(s): Home Telemedicine
D: Intervention Type: BEHAVIORAL; Name: Internet-based Dyspnea Self-Management Program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face Dyspnea Self-Management Program; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A RANDOMIZED, OPEN-LABEL, TWO-PERIOD STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETANERCEPT ON SKIN AND JOINT DISEASE IN PSORIASIS SUBJECTS WITH PSORIATIC ARTHRITIS
Brief Summary: The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.


Options:
A: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A
B: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab, Drug: placebo | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 140 mg brodalumab, 210 mg brodalumab, placebo
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A RANDOMIZED, OPEN-LABEL, TWO-PERIOD STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETANERCEPT ON SKIN AND JOINT DISEASE IN PSORIASIS SUBJECTS WITH PSORIATIC ARTHRITIS
Brief Summary: The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Immediate Methotrexate Cessation; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Gradual Reduction of Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Methotrexate | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Gradual Reduction of Methotrexate, Immediate Methotrexate Cessation | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Gradual Reduction of Methotrexate
C: Arm Label: Group I; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group II; Type: PLACEBO_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group III; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Adalimumab | Intervention Type: DRUG; Name: Guselkumab 100 mg; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Placebo for guselkumab; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Group III | Intervention Type: DRUG; Name: Placebo for adalimumab; Assigned to Arm(s): Group I, Group II
D: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A RANDOMIZED, OPEN-LABEL, TWO-PERIOD STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETANERCEPT ON SKIN AND JOINT DISEASE IN PSORIASIS SUBJECTS WITH PSORIATIC ARTHRITIS
Brief Summary: The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.


Options:
A: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
B: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab
C: Arm Label: Cohort A: INCB018424 Ruxolitinib 0.5%; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib phosphate cream, Drug: Placebo cream | Arm Label: Cohort B: INCB018424 Ruxolitinib 1.0%; Type: EXPERIMENTAL; Interventions: Drug: Placebo cream, Drug: Ruxolitinib phosphate cream | Arm Label: Cohort C: INCB018424 Ruxolitinib 1.5%; Type: EXPERIMENTAL; Interventions: Drug: Placebo cream, Drug: Ruxolitinib phosphate cream | Arm Label: Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene; Type: EXPERIMENTAL; Interventions: Drug: Dovonex® calcipotriene 0.005% | Arm Label: Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate; Type: EXPERIMENTAL; Interventions: Drug: Diprolene® AF betamethasone dipropionate 0.05% cream. | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort A: INCB018424 Ruxolitinib 0.5% | Intervention Type: DRUG; Name: Dovonex® calcipotriene 0.005%; Assigned to Arm(s): Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene | Intervention Type: DRUG; Name: Diprolene® AF betamethasone dipropionate 0.05% cream.; Assigned to Arm(s): Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate | Intervention Type: DRUG; Name: Placebo cream; Assigned to Arm(s): Cohort A: INCB018424 Ruxolitinib 0.5%, Cohort B: INCB018424 Ruxolitinib 1.0%, Cohort C: INCB018424 Ruxolitinib 1.5% | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort B: INCB018424 Ruxolitinib 1.0% | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort C: INCB018424 Ruxolitinib 1.5%
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A RANDOMIZED, OPEN-LABEL, TWO-PERIOD STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETANERCEPT ON SKIN AND JOINT DISEASE IN PSORIASIS SUBJECTS WITH PSORIATIC ARTHRITIS
Brief Summary: The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Induction Single Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Induction Monthly Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Induction Early Loading Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Placebo Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): Induction Single Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Monthly Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Early Loading Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Dose
C: Arm Label: Therapeutic drug monitoring; Type: EXPERIMENTAL; Interventions: Other: Therapeutic drug monitoring | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Therapeutic drug monitoring; Assigned to Arm(s): Therapeutic drug monitoring | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
D: Arm Label: BCD-085 Q2W; Type: EXPERIMENTAL; Interventions: Drug: BCD-085 Q2W | Arm Label: BCD-085 Q4W; Type: EXPERIMENTAL; Interventions: Drug: BCD-085 Q4W | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BCD-085 Q2W; Assigned to Arm(s): BCD-085 Q2W | Intervention Type: DRUG; Name: BCD-085 Q4W; Assigned to Arm(s): BCD-085 Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study To Evaluate the Safety And Efficacy Of Prolonged Release OROS Methylphenidate Hydrochloride (18, 36 and 72 mg/Day), With Open-Label Extension, In Adults With Attention Deficit/Hyperactivity Disorder
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of three doses of prolonged-release methylphenidate (a central nervous system (CNS) stimulant) in adult patients with attention deficit/hyperactivity disorder (ADHD).


Options:
A: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate; Assigned to Arm(s): N/A
C: Arm Label: Vyvanse (LDX); Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine Dimesylate | Arm Label: Adderall XR (AXR); Type: EXPERIMENTAL; Interventions: Drug: Adderall XR (mixed salts amphetamine) | Intervention Type: DRUG; Name: Lisdexamfetamine Dimesylate; Assigned to Arm(s): Vyvanse (LDX) | Intervention Type: DRUG; Name: Adderall XR (mixed salts amphetamine); Assigned to Arm(s): Adderall XR (AXR)
D: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study To Evaluate the Safety And Efficacy Of Prolonged Release OROS Methylphenidate Hydrochloride (18, 36 and 72 mg/Day), With Open-Label Extension, In Adults With Attention Deficit/Hyperactivity Disorder
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of three doses of prolonged-release methylphenidate (a central nervous system (CNS) stimulant) in adult patients with attention deficit/hyperactivity disorder (ADHD).


Options:
A: Intervention Type: DRUG; Name: methylphenidate hydrochloride extended-release tablets; Assigned to Arm(s): N/A
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: JNJ-31001074 1 mg/d | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: JNJ-31001074 3 mg/d | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: JNJ-31001074 10 mg/d | Arm Label: 004; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atomoxetine 80 mg/d | Arm Label: 005; Type: ACTIVE_COMPARATOR; Interventions: Drug: OROS methylphenidate HCl 54 mg/d | Arm Label: 006; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine 80 mg/d; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 006 | Intervention Type: DRUG; Name: OROS methylphenidate HCl 54 mg/d; Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: JNJ-31001074 3 mg/d; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: JNJ-31001074 1 mg/d; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: JNJ-31001074 10 mg/d; Assigned to Arm(s): 003
C: Intervention Type: DRUG; Name: naltrexone (Revia); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: acamprosate (Campral); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
Brief Summary: This study will evaluate the efficacy of diet and exercise (DE), with and without niacin and fenofibrate, in reducing the cardiovascular risk of patients with HIV lipodystrophy or dyslipidemia.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Vitamin D 4000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): Vitamin D 4000 IU | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Multiple RDA multivitamins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins (including B, C and E) | Arm Label: Single RDA Multivitamins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins B, C and E | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins (including B, C and E); Assigned to Arm(s): Multiple RDA multivitamins | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins B, C and E; Assigned to Arm(s): Single RDA Multivitamins
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebos | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Other: Placebos | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Niacin, Other: Placebos | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Fenofibrate, Other: Placebos | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Niacin, Drug: Fenofibrate | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): 2, 3, 4, 5 | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 2, 3, 4, 5 | Intervention Type: DRUG; Name: Niacin; Assigned to Arm(s): 3, 5 | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): 4, 5 | Intervention Type: OTHER; Name: Placebos; Assigned to Arm(s): 1, 2, 3, 4
D: Arm Label: 4000IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol (Vit D3) | Arm Label: 7000IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol (Vit D3) | Intervention Type: DRUG; Name: Cholecalciferol (Vit D3); Assigned to Arm(s): 4000IU, 7000IU

Answer: C